All this makes sense Avemaria, and I've just bought another few thousand @$2.88, but I'm thinking though that the whole 'we're still not really on anyone's radar yet' thing is starting to wear a bit thin. Retail perhaps yes, but the fundies are well aware of us I'm sure, and big pharmas are surely taking a close look at a company with a blockbuster drug which is trading for a pittance. So why all the lack of interest?
Wondering if perhaps the IP issue is a hotter potato than we thought...
Valuation and Targets, page-223
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
0.015(6.52%) |
Mkt cap ! $85.70M | |||
| Open | High | Low | Value | Volume |
| 24.0¢ | 28.0¢ | 24.0¢ | $352.6K | 1.410M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 97852 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.5¢ | 21502 | 1 |
View Market Depth
| Last trade - 16.10pm 20/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |